 |
|
|
| |
Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ± Ribavirin (RBV) in Chronic HCV Genotype (GT) 1-Infected Patients
Who Previously Failed Telaprevir (TVR) or Boceprevir (BOC)
|
| |
| |
Reported by Jules Levin
IDSA Oct 2-6 2013 San Francisco, CA
Sulkowski MS,1 Gardiner DF,2 Rodriguez-Torres M,3 Reddy KR,4 Hassanein T,5 Jacobson IM,6 Lawitz E,7 Lok AS,8 Hinestrosa F,9 Thuluvath PJ,10 Schwartz H,11 Nelson DR,12 Everson GT, 13 Eley T,2 Wind-Rotolo M,14 Huang S-P,14 Gao M,15
Hernandez D,15 McPhee F,15 Sherman D,2 Hindes R,16 Symonds W,17 Pasquinelli C,2 and Grasela DM2 for the AI444-040 Study Group
1Johns Hopkins University, Baltimore, MD; 2Bristol-Myers Squibb, Hopewell, NJ; 3Fundacion de Investigacion, San Juan, Puerto Rico; 4University of Pennsylvania, Philadelphia, PA; 5Southern California Liver Center, Coronado, CA; 6Weill Cornell Medical College, New York, NY; 7Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX; 8University of
Michigan, Ann Arbor, MI; 9Orlando Immunology Center, Orlando, FL; 10Mercy Medical Center, Baltimore, MD; 11Miami Research Associates, South Miami, FL; 12University of Florida, Gainesville, FL; 13University of Colorado Denver, Aurora, CO; 14Bristol-Myers Squibb, Princeton, NJ; 15Bristol-Myers Squibb, Wallingford, CT; 16Consultant; 17Gilead Sciences, Foster City, CA
|
| |
|
|
|
|
|
